Allarity opens Phase 2 trial of stenoparib + temozolomide in relapsed SCLC

Allarity Therapeutics, Inc.

Enrollment open at 11 VA sites for NCT06681220; trial fully funded by U.S. Department of Veterans Affairs.
Phase 2 evaluates stenoparib (dual PARP/WNT inhibitor) plus temozolomide in recurrent small cell lung cancer.
Study uses a blood-based biomarker to select patients most likely to benefit from the combination.
Stenoparib's favorable safety profile is cited as key rationale for combination with temozolomide.
Stenoparib crosses the blood-brain barrier, offering potential for brain metastases common in advanced SCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.